Ian Quigley was employee #13 at AI drug company Recursion until 2021, when he quit and turned the basement of his Utah home into a lab to develop AI models for predicting which proteins small molecule drugs might target — a tool he and co-founder Andrew Blevins found was missing during their time at Recursion.
When he was setting up the lab, Quigley ordered an Illumina DNA sequencer that the delivery person had wanted to leave on his porch. Freaked out by that idea, he instead picked it up in his Toyota Yaris, folding down the back seats to fit it next to his dog’s kennel.
In that basement lab, Quigley and his small team at Leash Bio produced about 133 million data points of small molecules binding to protein targets. Earlier this year, they released that data as training fodder in a competition aimed at determining whether any AI models for predicting small molecule interactions with proteins were really learning anything about biology, or just memorizing what they had seen before.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
